References
- Bastin J, Djouadi F. Resveratrol and myopathy. Nutrients. 2016;8:254. doi:10.3390/nu8050254.
- Waterhouse AL. Wine phenolics. Ann N Y Acad Sci. 2002;957:21–36.
- Soleas GJ, Diamandis EP, Goldberg DM. Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal. 1997;11:287–313.
- Wang Y, Catana F, Yang Y, et al. An LC–MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 2002;50:431–435.
- Song W, Wang HJ, Bucheli P, et al. Phytochemical profiles of different mulberry (Morus sp.) species from China. J Agric Food Chem. 2009;57:9133. doi:10.1021/jf9022228.
- Kim CW, Hwang KA, Choi KC. Anti-metastatic potential of resveratrol and its metabolites by the inhibition of epithelial–mesenchymal transition, migration, and invasion of malignant cancer cells. Phytomed Int J Phytother Phytopharmacol. 2016;23:1787–1796.
- Ahmad A, Farhan Asad S, Singh S, et al. DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation. Cancer Lett. 2000;154:29–37.
- Ahmad A, Syed FA, Singh S, et al. Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. Toxicol Lett. 2005;159:1–12.
- Pan J, Shen J, Si W, et al. Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway. Oncotarget. 2017;8:65743–65758..
- Shankar S, Nall D, Tang SN, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial–mesenchymal transition. PloS One. 2011;6:e16530. doi:10.1371/journal.pone.0016530.
- Roldan A, Palacios V, Caro I, et al. Resveratrol content of Palomino fino grapes: influence of vintage and fungal infection. J Agric Food Chem. 2003;51:1464–1468..
- Fremont L. Biological effects of resveratrol. Life Sci. 2000;66:663–673.
- Regev-Shoshani G, Shoseyov O, Kerem Z. Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biochem Biophys Res Commun. 2004;323:668–673.
- Piver B, Berthou F, Dreano Y, et al. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non-volatile red wine components. Toxicol Lett. 2001;125:83–91.
- Wang Y, Jiang Y, Fan X, et al. Hepato-protective effect of resveratrol against acetaminophen-induced liver injury is associated with inhibition of CYP-mediated bioactivation and regulation of SIRT1-p53 signaling pathways. Toxicol Lett. 2015;236:82–89.
- Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080.
- Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2:58–61.
- Scheers E, Leclercq L, de Jong J, et al. Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos Biol Fate Chem. 2014;43:289–297.
- Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. Peer Rev J Formula Manage. 2014;9:483–519.
- de Zwart L, Snoeys J, De Jong J, et al. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. 2016;100:548–557.
- de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015;3:e00156.
- Lambert Kuhn E, Leveque D, Lioure B, et al. Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. J Clin Pharm Ther. 2016;41:104–105.
- Ly JQ, Messick K, Qin A, et al. Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 transgenic mouse models to assess the magnitude of CYP3A4 mediated drug–drug interactions. Mol Pharm. 2017;1;14:1754–1759.
- Tobinai K, Ogura M, Ishizawa K, et al. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Int J Hematol. 2016;103:86–94.
- Maruyama D, Nagai H, Fukuhara N, et al. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Cancer Sci. 2016;107:1785–1790.